Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.36 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31730088 | 0.86 | ALDH1A1 (0.38) | ALDH1A1LMNAOPRL1MAPTGAA | |
| SCHEMBL15156486 | 0.77 | TP53 (0.52) | ALDH1A1LMNAOPRL1MAPTALDH3A1 | |
| SCHEMBL29347593 | 0.75 | ALDH1A1 (0.38) | ALDH1A1LMNAOPRL1MAPTALDH3A1 | |
| SCHEMBL9543551 | 0.73 | OPRL1 (0.48) | ALDH1A1LMNAOPRL1 | |
| SCHEMBL31748131 | 0.69 | ALDH1A1 (0.42) | ALDH1A1LMNAOPRL1MAPTALDH3A1 | |
| SCHEMBL29347277 | 0.69 | ALDH1A1 (0.42) | ALDH1A1LMNAOPRL1MAPTALDH3A1 | |
| SCHEMBL9544593 | 0.68 | OPRL1 (0.50) | ALDH1A1LMNAOPRL1 | |
| SCHEMBL31730106 | 0.66 | ALDH1A1 (0.41) | ALDH1A1LMNAOPRL1TSHRGAA | |
| SCHEMBL9541775 | 0.65 | TDP1 (0.51) | ALDH1A1LMNAOPRL1MAPTALDH3A1 | |
| SCHEMBL9774461 | 0.65 | TDP1 (0.42) | ALDH1A1LMNAOPRL1ALDH3A1ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | ALDH1A1 579/4885LMNA 3163/4885OPRL1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.